Status:
COMPLETED
Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
Arthritis Foundation
Conditions:
Systemic Lupus Erythematosus
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in patients with systemic lupus by measuring: 1. changes in brachial artery flow-mediated dilatation (FMD) and 2...
Eligibility Criteria
Inclusion
- Female
- Member of the Michigan Lupus Cohort
- Meet the American College of Rheumatology (ACR) criteria for SLE
- Premenopausal
Exclusion
- Smoker
- Diabetic
- Prednisone dose \> 10 mg
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00189124
Start Date
September 1 2003
End Date
July 1 2006
Last Update
May 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109